Vigabatrin associated retinal dysfunction in children with epilepsy

Background-Recent reports have established that eye changes occur in patien ts treated with vigabatrin. Aim-To identify the eye changes associated with vigabatrin, based on a pros pective study of children treated for seizures. Methods-Twenty nine children on vigabatrin (mainly as add on therapy) were followed up for 6.5 years. Ophthalmic examination was performed before star ting treatment and then six monthly in the outpatient clinic. Results-Twenty one children fulfilled the inclusion criteria. Most had epil eptic syndromes with infantile spasms-namely West syndrome, Lennox-Gastaut syndrome, and partial seizures. Vigabatrin dose was 25-114 mg/kg/day (mean 55.8); duration of therapy was 6-85 months (mean 35.7). Four children (19%) developed eye changes (retinal pigmentation, hypopigmented retinal spots, vascular sheathing, and optic atrophy). Visual evoked potentials were abnor mal in 16 children. Electroretinography and electro-oculography, which coul d have picked up eye changes in early stages, were not performed, as this f acility was not available. Conclusions-Vigabatrin causes eye damage. Most children with epileptic synd romes on vigabatrin cannot complain of their eye problems, hence 3-6 monthl y ophthalmic follow up is strongly advised, along with regular electroretin ography, electro-oculography, and visual evoked potentials if possible.